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Abstract: Somatostatin (SRIF)-14 is recognized
as an important mediator between the nervous and
the immune system, although the functional role of
its receptors (sst1–sst5) is poorly understood in hu-
mans. In our study, we demonstrate that human
macrophages, differentiated from PBMC-derived
monocytes, express sst1 and sst2 mRNAs. sst1 and
sst2 are mostly localized at the cell surface and
display active binding sites. In particular, sst1/sst2
activation results in a weak internalization of sst1,
and the sst2 internalization appears more efficient.
At the functional level, the activation of SRIF re-
ceptors by the multiligand analogs SOM230 and
KE108, but not by SRIF-14 or cortistatin-14, re-
duces macrophage viability. Their effects are mim-
icked by the selective activation of sst1 and sst2
using CH-275 and SMS 201-995/L-779,976, re-
spectively. Further, sst1- and sst2-mediated effects
are reversed by the sst1 antagonist SRA-880 or
the sst2 antagonist CYN 154806, respectively.
CH-275, SMS 201-995, and L-779,976, but not
SRIF-14, decrease mRNA expression and secre-
tion of the MCP-1. In addition, SRIF-14, CH-275,
SMS 201-995, and L-779,976 decrease IL-8 se-
cretion, and they do not affect IL-8 mRNA expres-
sion. In contrast, SRIF-14 and sst1/sst2 agonists do
not affect the secretion of matrix metalloprotein-
ase-9. Collectively, our results suggest that the
SRIF system, through sst1 and sst2, exerts mainly
an immunosuppressive effect in human macro-
phages and may, therefore, represent a therapeu-
tic window that can be exploited for the develop-
ment of new strategies in pharmacological therapy
of inflammation. J. Leukoc. Biol. 81: 845–855;
2007.
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INTRODUCTION
The complex network of communication between the nervous
and the immune system has become the subject of intense
research in recent years. To maintain the function of the
neuroimmune circuitry, cells in both systems produce diverse
chemical messengers, which are involved in the regulation of
immunological and inflammatory responses [1]. In particular,
cytokines and neuropeptides, which exist in the nervous and
immune system, are potential mediators of cross-talk between
the two systems. There is evidence to suggest that the circu-
lating neuropeptide somatostatin (SRIF)-14, acting through its
specific G protein-coupled receptors (sst1–5) [2, 3], is one such
mediator and may represent an important regulator of the
immune response [4, 5]. For example, SRIF-14 has potent,
modulatory actions on the release of Igs and cytokines. Fur-
thermore, the peptide is also involved in inhibition of chemo-
taxis, phagocytic activity, and the NK cell activity of immune
cells. In this respect, the synthetic SRIF analog TT232 has
recently become a therapeutic candidate with anti-inflamma-
tory indications and is currently under evaluation in clinical
trials [6].
Monocytes and macrophages are recognized as important
components of innate and acquired immunity. In rodent
cells of the monocyte lineage, the inhibitory role of SRIF-14
has been studied extensively [7–14]. However, in human
monocytes, the role of SRIF-14 is less well-understood, and
reported results have been controversial [5, 15]. Human
monocytes derived from PBMC do not express mRNA for
SRIF-14 [16 –18], and they do express the mRNA for cor-
tistatin [16, 17], a SRIF-14-like peptide, which may serve as
an alternative ligand for SRIF receptors in the immune
system [19, 20]. The presence of SRIF receptors in mono-
cytes has been suggested from binding studies [4, 5]. In
addition, sst2 mRNA has been observed in PBMC-derived
monocytes [17]; however, this expression was undetectable
under basal conditions and required cell activation to up-
regulate the mRNA to a level that could be detected [15].
Circulating monocytes are versatile precursor cells with the
ability to differentiate into various forms of specialized
macrophages [21, 22], a process that is influenced pro-
foundly by the cytokine milieu. The functional activation of
macrophages can occur by “classical” or “alternative” ac-
tivators, resulting in functionally polarized cells [23, 24].
The activation of macrophages by LPS is considered a
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